Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Olema Pharmaceuticals, Inc. (OLMA) had Income from Continuous Operations of $-162.45M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-162.45M |
|
-- |
|
-- |
|
$178.70M |
|
$-178.70M |
|
$16.25M |
|
$-162.45M |
|
$-162.45M |
|
$-162.45M |
|
|
Income from Continuous Operations |
$-162.45M |
$-162.45M |
|
$-162.45M |
|
$-178.70M |
|
$-178.21M |
|
87.01M |
|
87.01M |
|
$-1.87 |
|
$-1.87 |
|
| Balance Sheet Financials | |
$515.45M |
|
-- |
|
$17.98M |
|
$533.43M |
|
$51.80M |
|
$3.00M |
|
$3.07M |
|
$54.87M |
|
$478.56M |
|
$478.56M |
|
$478.56M |
|
81.38M |
|
| Cash Flow Statement Financials | |
$-146.72M |
|
$-155.76M |
|
$211.30M |
|
$139.48M |
|
$48.30M |
|
$-91.18M |
|
$17.59M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.95 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-146.72M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.95% |
|
-33.95% |
|
-30.45% |
|
-33.73% |
|
$5.88 |
|
$-1.69 |
|
$-1.69 |
|